The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models

  • Cancer Res Commun. 2025 Feb 1;5(2):240-252. doi: 10.1158/2767-9764.CRC-24-0411.
Nathan M Jameson  1 ,  Daehwan Kim  1 ,  Catherine Lee  1 ,  Blake Skrable  1 ,  Alexandra Shea  1 ,  Xiao Guo  1 ,  Hooman Izadi  1 ,  Mona Abed  1 ,  Olivier Harismendy  1 ,  Jianhui Ma  1 ,  Doris S Kim  1 ,  Mark R Lackner  1
Affiliations
  • 1. Zentalis Pharmaceuticals, Inc., San Diego, California.
PMID: 39807828 DOI: 10.1158/2767-9764.CRC-24-0411
Abstract

Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.

Products